ResourcesLearn from our biopharma experts, explore stimulating thought leadership and see some of our clients’ past successes.
Prescient has conducted research among competitive intelligence (CI) stakeholders throughout the biopharmaceutical industry to identify the top challenges in CI and to highlight the strategic imperatives and actionable recommendations to face these challenges head-on. We developed a white paper to summarize the research and provide our insights and expertise.
Will Your Brand Maintain Its Value in 2020? Key US Market Trends That Should Be Shaping Your Product and Portfolio StrategyBen Doran, Katy Chun and Jesmine Cheung
In this white paper, Prescient has identified three industry trends that are shaping competitive dynamics in the US market and how biopharmaceutical companies can optimize the performance of their brands. We discuss the impact and implications of these industry trends on brand teams and the strategies they can leverage to maximize their products’ potential. The following key trends have emerged:
Tumor mutational burden (TMB (the number of mutations per megabase of DNA (mut/Mb)) can be a predictor of response for single-agent immunotherapy, but it has failed to demonstrate any correlation with response when immunotherapy is combined with chemotherapy. The benefit of the combination can be maintained independent of TMB status, and evaluation of TMB is not required for making treatment decisions for patients eligible to receive combination therapy.
Skin diseases constitute one of the leading causes of health burden worldwide, measured as disability-adjusted life years (DALYs). Among skin diseases, psoriasis (PsO) carries the third-largest disability weight, which translates into health loss and poor quality of life (QoL)1. Globally, approximately 1-8% of the population suffers from PsO2, 3. Among PsO patients, the prevalence of psoriatic arthritis (PsA) is estimated to be between 6% and 41%3.
Activating mutations in the EGFR gene are found in about 10-12% of all non-small cell lung cancer (NSCLC) cases and around 50% of cases in East-Asian patients. Cancer in patients with mutations is driven by constitutive activation of EGFR-signaling pathways due to acquired mutations in the catalytic domain of the receptor rendering them amenable to EGFR-tyrosine kinase inhibition1.
Lung cancer is the leading cause of cancer mortality worldwide, accounting for more than 1.6 million deaths annually. Non-small cell lung cancer (NSCLC) accounts for 85% of all new cases. Current first-line treatment decisions for metastatic NSCLC mandate analysis of the genetic status of the cancer to determine the presence of driver mutations, such as activating mutations in the epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK).
Breast cancer is the most common cancer in women with more than 2.1 million new cases diagnosed in 2018. And with more than 600,000 deaths in 2018, it is the second-leading cause of cancer deaths in women worldwide (WHO). Advances have been made across all stages and sub-types of the disease and provide hope for improved treatment options, lower rates of relapse and better survival outcomes.
The Prescient team has prepared a white paper discussing our view on the recent advances in the CAR-T landscape. In this paper, we do not focus on the already well-documented challenges, but rather present our view on the recent advances in the relatively short period of time since the first regulatory approvals. Industry and academia appear to be making significant strides in simplifying manufacturing and administration processes, expanding clinical utility and enabling access for patients.
A largely glossed-over finding from active-controlled trials of checkpoint inhibitors in solid tumors is the delayed crossover of Kaplan-Meier (K-M) survival curves, consistent with increased risk of disease progression and mortality early in checkpoint inhibitor immunotherapy (CPI). This raises the heretical proposition that CPI monotherapy may have a detrimental effect on progression and survival, early in treatment, relative to chemotherapy, in a significant number of patients.
Our client was a global biopharmaceutical company with a market-leading brand more than 20 years’ old. It came under intense pricing pressure due to generic entries from companies known to play primarily on price. The company faced issues in identifying key investment areas to help maintain the brand’s market leader position. Prescient was engaged to reevaluate the client’s business model through a series of projects designed to help the client